SIMULECT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SIMULECT (SIMULECT).
Basiliximab is a chimeric monoclonal antibody that binds to the alpha subunit of the interleukin-2 receptor (CD25) on activated T lymphocytes, thereby inhibiting IL-2-mediated activation and proliferation of T cells, which is a key pathway in acute rejection.
| Metabolism | Basiliximab is metabolized via proteolytic degradation into small peptides and amino acids; no specific metabolic enzymes are involved. |
| Excretion | Primarily eliminated by binding to IL-2 receptor and subsequent internalization and degradation; renal clearance of free antibody is minimal (<1%). |
| Half-life | Terminal half-life approximately 7.1 days (range 3.4–18.7 days) in renal transplant patients; shorter in pediatric patients. |
| Protein binding | ~0% binding to plasma proteins; basiliximab is a chimeric monoclonal antibody and does not bind to albumin or other proteins. |
| Volume of Distribution | Vd approximately 2.9 L (0.04 L/kg for a 70 kg adult); primarily distributed in vascular space and extracellular fluid. |
| Bioavailability | Only administered IV; bioavailability 100%. |
| Onset of Action | IV: Onset of immunosuppression within 30 minutes of infusion; peak IL-2 receptor saturation achieved immediately. |
| Duration of Action | Duration of IL-2 receptor blockade: ~60 days after two doses (day 0 and day 4). Clinical immunosuppression persists for weeks. |
| Action Class | IL-2 Receptor anatgonist |
Induction: 20 mg IV on day 0 and day 4 post-transplant.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Induction for patients <40 kg: 12 mg/m² IV on day 0 and day 4. For patients ≥40 kg: 20 mg IV on day 0 and day 4. |
| Geriatric use | No specific dose adjustment; monitor renal function and immune response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SIMULECT (SIMULECT).
| Breastfeeding | Basiliximab is likely present in human milk due to its large molecular size (IgG1), though M/P ratio is unknown. Excretion into breast milk is expected to be low, but potential for absorption by the nursing infant exists. Caution is advised; consider the developmental and health benefits of breastfeeding against the mother's clinical need. |
| Teratogenic Risk | Basiliximab (Simulect) is a monoclonal antibody (IgG1) that crosses the placenta, particularly during the second and third trimesters. Animal studies have not shown direct teratogenicity, but human data are limited. The theoretical risk includes potential immunosuppression of the fetus. Use during pregnancy should be avoided unless the benefit outweighs the risk; third-trimester exposure may increase infection risk in the neonate. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to basiliximab or any components of the formulation."]
| Precautions | ["Risk of hypersensitivity reactions, including anaphylaxis, which may be severe.","Risk of infections and lymphoproliferative disorders due to immunosuppression.","Patients should be monitored for cytomegalovirus (CMV) infection.","Use in pregnancy: Pregnancy category B; risk to fetus cannot be excluded.","Immunization: Live vaccines should not be administered during therapy."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal infections, infusion reactions, and signs of immunosuppression. Fetal monitoring includes serial ultrasound to assess growth and well-being, especially with prolonged exposure. Neonatal monitoring for infection and immune function is recommended after in utero exposure. |
| Fertility Effects | Basiliximab is not known to directly impact fertility. No human studies on fertility exist; animal studies did not show impaired fertility. However, the underlying condition requiring immunosuppression may affect fertility indirectly. |